Rezolute (RZLT) Income towards Parent Company (2012 - 2026)
Rezolute (RZLT) reported Income towards Parent Company of -$20.9 million for Q1 2026, up 13.68% on a YoY basis from -$18.4 million in Q1 2025, and up 17.2% sequentially from -$25.3 million in Q4 2025.
Rezolute (RZLT) Income towards Parent Company (2012 - 2026) Analysis & Trends
Rezolute (RZLT) has 15 years of Income towards Parent Company data on file, last reported at -$20.9 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company rose 13.68% year-over-year to -$20.9 million; the trailing twelve-month figure through Mar 2026 stood at -$163.3 million (down 43.66% YoY), and the FY2025 full-year result was -$164.3 million, down 105.04% from the prior year.
- Income towards Parent Company climbed to -$20.9 million in Q1 2026, from -$25.3 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$10.0 million in Q3 2022 to a low of -$92.5 million in Q3 2025.
- A 5-year average of -$23.7 million and a median of -$19.8 million in 2024 frame the typical range for Income towards Parent Company.
- Peak annual rise in Income towards Parent Company reached 27.66% in 2025, while the deepest fall reached 158.47% in 2025.
- Tracing RZLT's Income towards Parent Company over 5 years: stood at -$14.1 million in 2022, then slipped by 0.68% to -$14.2 million in 2023, then plunged by 145.39% to -$34.9 million in 2024, then rose by 27.66% to -$25.3 million in 2025, then advanced by 17.2% to -$20.9 million in 2026.
- Business Quant data shows RZLT's Income towards Parent Company at -$20.9 million in Q1 2026, -$25.3 million in Q4 2025, and -$92.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Rezolute | 518.12 Mn | 518.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.93 Mn |
| Dec 31, 2025 | -25.27 Mn |
| Sep 30, 2025 | -92.46 Mn |
| Jun 30, 2025 | -24.59 Mn |
| Mar 31, 2025 | -24.24 Mn |
| Dec 31, 2024 | -34.94 Mn |
| Sep 30, 2024 | -35.77 Mn |
| Jun 30, 2024 | -18.69 Mn |
| Mar 31, 2024 | -19.84 Mn |
| Dec 31, 2023 | -14.24 Mn |
| Sep 30, 2023 | -15.18 Mn |
| Jun 30, 2023 | -10.03 Mn |
| Mar 31, 2023 | -20.21 Mn |
| Dec 31, 2022 | -14.14 Mn |
| Sep 30, 2022 | -9.99 Mn |
| Jun 30, 2022 | -11.71 Mn |
| Mar 31, 2022 | -11.45 Mn |
| Dec 31, 2021 | -12.84 Mn |
| Sep 30, 2021 | -8.34 Mn |
| Jun 30, 2021 | -6.66 Mn |